Correlation of Hypothyroidism and Obesity

Т.Y. Yuzvenko

Abstract


Obesity and hypothyroidism are common diseases, and consequently clinicians should be particularly alert for the possible thyroid dysfunction in obese patients. The relationship between thyroid function and obesity is likely to be bidirectional, with hypothyroidism affecting weight, but obesity also influencing thyroid function. Both serum thyroid-stimulating hormone and fT3 are typically increased in obese individuals, likely mediated by leptin. Following LT4 treatment for overt hypothyroidism, weight loss appears due to water weight rather than fat. Selected thyroid analogs might be a means to improve weight loss by increasing energy expenditure in obese patients during lasting hypocaloric diet.


Keywords


obesity; hypothyroidism

References


Alevizaki M, Saltiki K, Voidonikola P. et al. Free thyroxine is an independent predictor of subcutaneous fat in euthyroid individuals. Eur J Endocrinol. 2009; 16: 459–465.

Antonelli A, Fallahi P, Ferrari SM. et al. 3,5-diiodo-L-thyronine increases resting metabolic rate and reduces body weight without undesirable side effects. J Biol Regul Homeost Agents. 2011; 25: 655–660.

Bastemir M, Akin F, Alkis E. et al. Obesity is associated with increased serum TSH level, independent of thyroid function. Swiss. Med. Wkly. 2007;137:29–30.

Baxter JD, Webb P. Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes. Nat Rev Drug Discov 2009; 8:308–320.

Boeving A, Paz-Filho G, Radominski RB, et al. Low-normal or high-normal thyrotropin target levels during treatment of hypothyroidism: a prospective, comparative study. Thyroid 2011; 21:355–360.

Celi FS, Zemskova M, Linderman JD, et al. Metabolic effects of liothyronine therapy in hypothyroidism: a randomized, double-blind, crossover trial of liothyronine versus levothyroxine. J Clin Endocrinol Metab. 2011;96:3466–3474.

De Pergola G, Ciampolillo A, Paolotti S, Trerotoli P, Giorgino R. Free triiodothyronine and thyroid stimulating hormone are directly associated with waist circumference, independently of insulin resistance, metabolic parameters and blood pressure in overweight and obese women. Clin Endocrinol (Oxf). 2007;67:265–266.

Garber J.R., Cobin R.H., Gharib H.,Hennessey J.V., Klein I., Mechanick J.I.,Pessah Pollack R., Singer P.A., Woeber K.A.Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association Endocr. Pract. 2012;11:1–207.

Karmisholt J, Andersen S, Laurberg P. Weight loss after therapy of hypothyroidism is mainly caused by excretion of excess body water associated with myxoedema. J Clin Endocrinol Metab. 2011; 96:99–103.

Kaptein EM, Beale E, Chan LS. Thyroid hormone therapy for obesity and nonthyroidal illnesses: a systematic review. J Clin Endocrinol Metab. 2009; 94:3663–3675.

Ladenson PW, Kristensen JD, Ridgway EC. et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med. 2010; 362:906–916.

Lu S, Guan Q, Liu Y. et al. Role of extrathyroidal TSHR expression in adipocyte differentiation and its association with obesity. Lipids Health Dis. 2012;11:17.

Ortega FJ, Moreno-Navarrete JM, Ribas V. et al. Subcutaneous fat shows higher thyroid hormone receptor-alpha1 gene expression than omental fat. Obesity (Silver Spring). 2009;17:2134–2141.

Polotsky HN, Brokhin M, Omry G, et al. Iatrogenic hyperthyroidism does not promote weight loss or prevent ageing-related increases in body mass in thyroid cancer survivors. Clin Endocrinol (Oxf). 2012;76:582–585.

Rotondi M, Cappelli C, Leporati P. A hypoechoic pattern of the thyroid at ultrasound does not indicate autoimmune thyroid diseases in patients with morbid obesity. European Journal of Endocrinology. 2010;163:105–109.

Svare A, Nilsen TI, Bjøro T, et al. Serum TSH related to measures of body mass: longitudinal data from the HUNT Study, Norway. Clin Endocrinol (Oxf). 2011;74:769–775.

Tang MH, Chen SP, Ng SW. et al. Case series on a diversity of illicit weightreducing agents: from the well known to the unexpected. Br J Clin Pharmacol. 2011;71:250–253.




DOI: https://doi.org/10.22141/2224-0721.8.80.2016.89530

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru